Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation :The atherosclerosis risk in communities study

Circulation: Arrhythmia and Electrophysiology

Volumn 5, Issue 1, 2012, Pages 155-162

  Lopez, Faye L ^a   Agarwal, Sunil K ^b   MacLehose, Richard F ^a   Soliman, Elsayed Z ^c   Sharrett, A Richey ^d   Huxley, Rachel R ^a   Konety, Suma ^a   Ballantyne, Christie M ^e,f   Alonso, Alvaro ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Atrial fibrillation; Epidemiology; Lipids; Statins

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORRELATION ANALYSIS; DRUG UTILIZATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84858326461     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.111.966804     Document Type: Article

References (36)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375 (Pubitemid 32424106)
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 1994;271:840-844
3. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111-117
4. Sanoski CA. Prevalence, pathogenesis, and impact of atrial fibrillation. Am J Health Syst Pharm. 2010;67:S11-S16
5. Wang TJ, Parise H, Levy D, D'Agostino RBS, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-2477 (Pubitemid 39552671)
6. Marcus GM, Alonso A, Peralta CA, Lettre G, Vittinghoff E, Lubitz SA, Fox ER, Levitzky YS, Mehra R, Kerr KF, Deo R, Sotoodehnia N, Akylbekova M, Ellinor PT, Paltoo DN, Soliman EZ, Benjamin EJ, Heckbert SR, Candidate-Gene Association Resource (CARe) Study. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation. 2010;122:2009-2015
7. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;159:850-856
8. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A; ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54:2023-2031
9. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. Circ J 2011;75:2767-2774
10. Goonasekara CL, Balse E, Hatem S, Steele DF, Fedida D. Cholesterol and cardiac arrhythmias. Expert Rev Cardiovasc Ther. 2010;8:965-979
11. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461 (Pubitemid 27425856)
12. Guize L, Pannier B, Thomas F, Bean K, Jego B, Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577-583
13. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation: The Niigata preventive medicine study. Circulation. 2008;117: 1255-1260 (Pubitemid 351365676)
14. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: Morbidity and risk factors. J Intern Med. 2001;250:382-389 (Pubitemid 32989592)
15. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit. 2009;15:MS1-MS5
16. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110:2313-2319 (Pubitemid 39407332)
17. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation: A meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51: 828-835 (Pubitemid 351255618)
18. Adam O, Neuberger HR, Bohm M, Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation. 2008;118:1285-1293
19. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Impact of lipid-lowering therapy on outcomes in atrial fibrillation. Am J Cardiol. 2010;105:1768-1772
20. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92: 1379-1383 (Pubitemid 37532555)
21. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126:160-170 (Pubitemid 351602110)
22. Soliman EZ, Prineas RJ, Case LD, Zhang ZM, Goff DC Jr. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40: 1204-1211
23. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol. 1989;129:687-702
24. Lipid and Lipoprotein Determinations: Atherosclerosis Risk in Communities (ARIC) Study: Manual 8. National Heart Lung and Blood Institute (NIH). Chapel Hill, North Carolina: ARIC Coordinating Center, University of North Carolina, 1987, updated 2005
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502
26. Eriksson H, Caidahl K, Larsson B, Ohlson LO, Welin L, Wilhelmsen L, Svardsudd K. Cardiac and pulmonary causes of dyspnoea: Validation of a scoring test for clinical-epidemiological use: The Study of Men Born in 1913. Eur Heart J. 1987;8:1007-1014 (Pubitemid 17133021)
27. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101:1016-1022
28. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: Methods and initial two years' experience. J Clin Epidemiol 1996;49:223-233 (Pubitemid 26123934)
29. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743 (Pubitemid 29156360)
30. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of the High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Available at: Http://www.nhlbi.nih.gov/guidelines/ cholesterol/atp3 rpt.htm. Accessed October 9, 2010
31. Oakes JM, Church TR. Invited commentary: Advancing propensity score methods in epidemiology. Am J Epidemiol. 2007;165:1119-1121; discussion 1122-1123 (Pubitemid 47233722)
32. Iguchi Y, Kimura K, Shibazaki K, Aoki J, Kobayashi K, Sakai K, Sakamoto Y. Annual incidence of atrial fibrillation and related factors in adults. Am J Cardiol. 2010;106:1129-1133
33. Duntas LH. Thyroid disease and lipids. Thyroid. 2002;12:287-293 (Pubitemid 34438931)
34. Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman A, Peeters RP, Hop WC, den Heijer M, Visser TJ, Witteman JC. High-normal thyroid function and risk of atrial fibrillation: The Rotterdam study. Arch Intern Med. 2008;168:2219-2224
35. Abi-Char J, Maguy A, Coulombe A, Balse E, Ratajczak P, Samuel JL, Nattel S, Hatem SN. Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. J Physiol. 2007; 582:1205-1217 (Pubitemid 47104349)
36. Balse E, El-Haou S, Dillanian G, Dauphin A, Eldstrom J, Fedida D, Coulombe A, Hatem SN. Cholesterol modulates the recruitment of Kv1.5 channels from Rab11-associated recycling endosome in native atrial myocytes. Proc Natl Acad Sci U S A. 2009;106:14681-14686.